Autolus Therapeutics Ltd

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally. Its product AUCATZYL is a gene therapy consisting of autologous T cells transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. The company also develops obe-cel in phase 1 for systemic lupus erythematosus, progressive multiple sclerosis, B-NHL, CLL, and CNS lymphoma, and in phase 2 for pediatric B-ALL and lupus nephritis. Additional programs include AUTO1/22 (phase 1 for pediatric B-ALL), AUTO8 (phase 1 for multiple myeloma and light chain amyloidosis), AUTO4/5 (preclinical for peripheral TCL), AUTO6NG (phase 1 for neuroblastoma), and AUTO9 (preclinical for acute myeloid leukemia). Autolus was incorporated in 2014 and is headquartered in London, United Kingdom.